CN107307417A - 一种ii型糖尿病患者用营养品 - Google Patents
一种ii型糖尿病患者用营养品 Download PDFInfo
- Publication number
- CN107307417A CN107307417A CN201710460014.5A CN201710460014A CN107307417A CN 107307417 A CN107307417 A CN 107307417A CN 201710460014 A CN201710460014 A CN 201710460014A CN 107307417 A CN107307417 A CN 107307417A
- Authority
- CN
- China
- Prior art keywords
- probiotics
- nutriment
- type
- prebiotics
- fruit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 23
- 239000006041 probiotic Substances 0.000 claims abstract description 22
- 235000018291 probiotics Nutrition 0.000 claims abstract description 22
- 239000000835 fiber Substances 0.000 claims abstract description 19
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 19
- 235000019216 blueberry extract Nutrition 0.000 claims abstract description 18
- 229940055416 blueberry extract Drugs 0.000 claims abstract description 18
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 14
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 14
- 229920001503 Glucan Polymers 0.000 claims description 3
- 241000209140 Triticum Species 0.000 claims 2
- 235000021307 Triticum Nutrition 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 7
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- 206010000060 Abdominal distension Diseases 0.000 abstract description 5
- 206010012735 Diarrhoea Diseases 0.000 abstract description 5
- 230000000968 intestinal effect Effects 0.000 abstract description 5
- 206010047700 Vomiting Diseases 0.000 abstract description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 229930014669 anthocyanidin Natural products 0.000 description 3
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 3
- 235000008758 anthocyanidins Nutrition 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 210000000110 microvilli Anatomy 0.000 description 3
- 239000003538 oral antidiabetic agent Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 235000009815 Momordica Nutrition 0.000 description 2
- 241000218984 Momordica Species 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 1
- 235000018365 Momordica dioica Nutrition 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种II型糖尿病患者用营养品，包括以下组分：果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌。由于果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌调节人体肠道菌群平衡可以抵消二甲双胍导致的腹泻、恶心、呕吐、腹胀及口腔异味的消化道反应，解决了现有II型糖尿病患者服用二甲双胍对人体造成的副作用的技术问题。
Description
技术领域
本发明涉及一种II型糖尿病患者用营养品。
背景技术
中国约有1.1亿名糖尿病患者，约占中国成年人总数的1/10。若不尽快采取行动，减少不健康饮食和缺乏运动等生活方式中的危险因素，预计该数字将在2040年增至1.5亿人，给民众健康和社会经济带来严重影响。其中II型糖尿病占糖尿病患者90％以上。II型糖尿病患者体内产生胰岛素的能力并非完全丧失，有的患者体内胰岛素甚至产生过多，但胰岛素的作用效果较差，因此患者体内的胰岛素是一种相对缺乏，可以通过某些口服药物刺激体内胰岛素的分泌。
二甲双胍是一种双胍类口服降血糖药,为目前临床使用最为普遍的口服降血糖药物之一，是目前一线核心的口服降糖药物，用于单纯饮食控制不满意的II型糖尿病病人，尤其是肥胖和伴高胰岛素血症者。二甲双胍主要通过肠道的摄取，提高胰岛素敏感性而增加外周葡萄糖的利用，以及抑制肝、肾过度的糖原异生，不降低非糖尿病患者的血糖水平。
二甲双胍的副作用主要包括大部分服二甲双胍后会出现消化道反应，如腹泻、恶心、呕吐、腹胀、口腔异味等，长期服用也容易产生胰岛素抵抗，药效降低，常常联合服用多种口服降糖药物，又会产生肝脏、肾脏的药源型损伤。
发明内容：
本发明涉及一种II型糖尿病患者用营养品，在II型糖尿病患者服用二甲双胍后再服用本发明的营养品后，可以克服二甲双胍对人体造成的副作用反应，以解决现有II型糖尿病患者服用二甲双胍对人体造成的副作用的技术问题。
为了解决以上技术问题，本发明采取的技术方案是：
一种II型糖尿病患者用营养品，其特征是，包括以下组分：果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌。
所述果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌所占比重分别为：
果蔬纤维 40％-60％
益生元 20％-30％
燕麦葡聚糖 5％-15％
蓝莓提取物 5％-15％
苦瓜提取物 1％-5％
益生菌 1％-5％。
所述II型糖尿病患者用营养品不再含有其它组分。
所述果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌所占比重分别为：
果蔬纤维 50％
益生元 20％
燕麦葡聚糖 10％
蓝莓提取物 15％
苦瓜提取物 2％
益生菌 3％。
在采用了上述技术方案后，由于果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌调节人体肠道菌群平衡，各组分的作用机制和协同机制，可以抵消二甲双胍导致的腹泻、恶心、呕吐、腹胀及口腔异味的消化道反应，解决了现有II型糖尿病患者服用二甲双胍对人体造成的副作用的技术问题。同时还可以增加二甲双胍的疗效，增加二甲双胍的抵御胰岛素抵抗的能力，逐步减少口服二甲双胍的用药量。
具体实施方式
一种II型糖尿病患者用营养品，包括以下组分：果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌。果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌所占比重分别为：
果蔬纤维 40％-60％
益生元 20％-30％
燕麦葡聚糖 5％-15％
蓝莓提取物 5％-15％
苦瓜提取物 1％-5％
益生菌 1％-5％
各组分的具体的配比如下表(以总重量为100克为例)：
由于人体口服营养品量有限，尤其是病人，本II型糖尿病患者用营养品不含有其它组分时效果最佳，很明显，由于是营养品，搀入其它对人体无害的组分当然也可以。本发明的营养品，其主要应用于II型糖尿病的辅助治疗，其通过调节人体肠道菌群平衡，可以抵消二甲双胍导致的腹泻、恶心、呕吐、腹胀及口腔异味的消化道反应，还可以增加二甲双胍的疗效，增加二甲双胍的抵御胰岛素抵抗的能力，可以逐步减少口服二甲双胍的用药量。
本发明涉及的医用营养品通过调节人体肠道菌群平衡，
1、配方组分的作用机制
·肠道菌群调控机制
主要涉及本发明的果蔬纤维、益生元以及益生菌三个成分的作用。其中果蔬纤维和益生元可以共同促进益生菌(含乳酸杆菌和双歧杆菌)的增殖，创造一个益生菌数量快速增加的环境。从而提高益生菌/致病菌的比例，可以直接改善二甲双胍引起的腹泻、恶心、呕吐、腹胀等副作用。
·燕麦葡聚糖
主要通过结肠紧密连接蛋白通路，改善肠黏膜机械屏障和生物屏障的损伤,起到保护肠黏膜屏障的作用。从而降低二甲双胍的副作用。
·蓝莓提取物作用机制
蓝莓提取物只要通过花青素发挥作用，花青素是一种天然抗氧化剂。花青素含有多个酚性羟基，在体内被氧化后释放出H+，竞争性地与自由基及氧化物结合，从而保护脂质不被氧化，阻断自由基链式反应。通过有效清除肠道内有害自由基，降低二甲双胍的副作用。
·苦瓜提取物作用机制
苦瓜提取物只要通过苦瓜皂甙发挥作用，苦瓜皂甙主要作用于肠道刷状缘。通过影响α－葡萄糖苷酶，其存在于小肠刷状缘膜的近腔上皮细胞内，主要作用是使淀粉、糊精、麦芽糖和蔗糖等降解为单糖。α－糖苷酶抑制剂是目前研究较多的糖尿病口服降糖药物，对葡萄糖苷酶有高度的亲和性，作用在小肠粘膜刷状缘，可通过延缓碳水化合物在肠道的消化和吸收，抑制餐后血糖水平的升高，同时在一定程度上能降低空腹血糖。
·协同作用机制
主要通过本发明涉及的果蔬纤维、益生元和益生菌共同作用，营造一个益生菌可以快速增值，甚至占主导的肠道菌群环境；并且通过本发明涉及的燕麦葡聚糖对肠道黏膜的修复和保护；蓝莓提取物对肠道内有害自由基的清除，以及苦瓜提取物主要于肠道刷状缘，延缓碳水化合物在肠道的消化和吸收，四个不同的作用途径，降低二甲双胍由于对消化道的刺激导致的副作用，从而提高二甲双胍的作用疗效。
Claims (4)
1.一种II型糖尿病患者用营养品，其特征是，包括以下组分：果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌。
2.如权利要求1所述的II型糖尿病患者用营养品，其特征是，所述果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌所占比重分别为：
果蔬纤维40％-60％
益生元20％-30％
燕麦葡聚糖5％-15％
蓝莓提取物5％-15％
苦瓜提取物1％-5％
益生菌1％-5％。
3.如权利要求1或2所述的II型糖尿病患者用营养品，其特征是，所述II型糖尿病患者用营养品不再含有其它组分。
4.如权利要求3所述的II型糖尿病患者用营养品，其特征是，所述果蔬纤维、益生元、燕麦葡聚糖、蓝莓提取物、苦瓜提取物和益生菌所占比重分别为：
果蔬纤维50％
益生元20％
燕麦葡聚糖10％
蓝莓提取物15％
苦瓜提取物2％
益生菌3％。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710460014.5A CN107307417A (zh) | 2017-06-17 | 2017-06-17 | 一种ii型糖尿病患者用营养品 |
| PCT/CN2017/097584 WO2018227749A1 (zh) | 2017-06-17 | 2017-08-16 | 一种ii型糖尿病患者用营养品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710460014.5A CN107307417A (zh) | 2017-06-17 | 2017-06-17 | 一种ii型糖尿病患者用营养品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107307417A true CN107307417A (zh) | 2017-11-03 |
Family
ID=60181827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710460014.5A Pending CN107307417A (zh) | 2017-06-17 | 2017-06-17 | 一种ii型糖尿病患者用营养品 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN107307417A (zh) |
| WO (1) | WO2018227749A1 (zh) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1520857A (zh) * | 2003-01-27 | 2004-08-18 | 永 张 | 一种治疗糖尿病的苦瓜中药制剂 |
| CN102488220A (zh) * | 2011-11-28 | 2012-06-13 | 中哈福生物医药科技（上海）有限公司 | 降血糖组合物，其制备方法及具有降血糖功能的保健食品 |
| CN102630948A (zh) * | 2012-04-19 | 2012-08-15 | 保龄宝生物股份有限公司 | 一种高纤无糖果味型复合益生元及其制备方法 |
| CN104127594A (zh) * | 2014-08-14 | 2014-11-05 | 孙战强 | 应用于糖尿病预防与控制的植物提取组合物 |
| CN104187670A (zh) * | 2014-09-02 | 2014-12-10 | 高鹏 | 一种辅助糖尿病人调节血糖的特殊膳食配方 |
| CN104489646A (zh) * | 2014-11-19 | 2015-04-08 | 李雅君 | 一种果蔬益生菌片剂及其制备方法 |
| CN105661547A (zh) * | 2016-01-22 | 2016-06-15 | 湖南营养树科技有限公司 | 一种益生菌复配蚕桑的糖尿病人营养补充剂 |
| CN105661245A (zh) * | 2016-01-29 | 2016-06-15 | 江苏微康生物科技有限公司 | 一种益生菌型果蔬酵素固体饮料 |
| CN106619743A (zh) * | 2016-12-28 | 2017-05-10 | 山东龙力生物科技股份有限公司 | 一种具有降血糖作用的益生菌固体饮料及其制备方法 |
| CN106689959A (zh) * | 2017-01-10 | 2017-05-24 | 唐山金鼎盛生物科技有限公司 | 一种辅助调节血糖的固体饮料 |
-
2017
- 2017-06-17 CN CN201710460014.5A patent/CN107307417A/zh active Pending
- 2017-08-16 WO PCT/CN2017/097584 patent/WO2018227749A1/zh active Application Filing
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1520857A (zh) * | 2003-01-27 | 2004-08-18 | 永 张 | 一种治疗糖尿病的苦瓜中药制剂 |
| CN102488220A (zh) * | 2011-11-28 | 2012-06-13 | 中哈福生物医药科技（上海）有限公司 | 降血糖组合物，其制备方法及具有降血糖功能的保健食品 |
| CN102630948A (zh) * | 2012-04-19 | 2012-08-15 | 保龄宝生物股份有限公司 | 一种高纤无糖果味型复合益生元及其制备方法 |
| CN104127594A (zh) * | 2014-08-14 | 2014-11-05 | 孙战强 | 应用于糖尿病预防与控制的植物提取组合物 |
| CN104187670A (zh) * | 2014-09-02 | 2014-12-10 | 高鹏 | 一种辅助糖尿病人调节血糖的特殊膳食配方 |
| CN104489646A (zh) * | 2014-11-19 | 2015-04-08 | 李雅君 | 一种果蔬益生菌片剂及其制备方法 |
| CN105661547A (zh) * | 2016-01-22 | 2016-06-15 | 湖南营养树科技有限公司 | 一种益生菌复配蚕桑的糖尿病人营养补充剂 |
| CN105661245A (zh) * | 2016-01-29 | 2016-06-15 | 江苏微康生物科技有限公司 | 一种益生菌型果蔬酵素固体饮料 |
| CN106619743A (zh) * | 2016-12-28 | 2017-05-10 | 山东龙力生物科技股份有限公司 | 一种具有降血糖作用的益生菌固体饮料及其制备方法 |
| CN106689959A (zh) * | 2017-01-10 | 2017-05-24 | 唐山金鼎盛生物科技有限公司 | 一种辅助调节血糖的固体饮料 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018227749A1 (zh) | 2018-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11213543B2 (en) | Human gastrointestinal microbiome modulating composition and methods of use | |
| CN103238897B (zh) | 一种适用于糖尿病人的复合植物固体饮料 | |
| TW201402129A (zh) | 包含蘿蔔硫素之組成物或包含一種蘿蔔硫素前驅物及一種奶薊萃取物或奶薊粉末之組成物 | |
| JP2020172523A (ja) | ユウリコマ・ロンギフォリア抽出物並びに免疫系の増強及び／又は刺激におけるその使用 | |
| TWI406666B (zh) | Niu Zhangzhi for the treatment of diseases | |
| JP7011885B2 (ja) | 腸の健康を促す組成物 | |
| US11266668B2 (en) | Dietary supplement for glycemia control and diabetes prevention | |
| McRorie Jr et al. | Psyllium: The gel-forming nonfermented isolated fiber that delivers multiple fiber-related health benefits | |
| RU2661622C1 (ru) | Твердофазная композиция природных биоактивных ингредиентов для коррекции метаболических нарушений при сахарном диабете второго типа | |
| Scarpellini et al. | Efficacy of butyrate in the treatment of diarrhoea-predominant irritable bowel syndrome | |
| CN103446166B (zh) | 肝功能改善剂 | |
| ES2949270T3 (es) | Uso de un portador farmacéutico en la preparación de una composición farmacéutica antidiabética que comprende berberina y orizanol | |
| US10757961B2 (en) | Dietary supplement for glycemia control and diabetes prevention | |
| TW201912171A (zh) | 戈氏副擬桿菌用於降低胰島素抗性及提升葡萄糖耐受性之用途 | |
| ES2867927T3 (es) | Composición para el tratamiento de una enfermedad diabética | |
| CN107307417A (zh) | 一种ii型糖尿病患者用营养品 | |
| Mahboubi | Prunus domestica as effective and acceptable treatment for stool softening and relief of constipation symptoms. | |
| CN107136499A (zh) | 用于肿瘤病人术后增强免疫力的复方制剂 | |
| Wu et al. | Burdock essence promotes gastrointestinal mucosal repair in ulcer patients | |
| EP3235510A1 (en) | Nutritional compositions for the management of glucose metabolism | |
| JP7177696B2 (ja) | 生理活性ペプチド又は生理活性タンパク質の活性低下抑制剤 | |
| EP3866615B1 (en) | Dietary supplement for treating dysbiosis | |
| CN103355665B (zh) | 一种用于辅助降血糖的组合物 | |
| CN113598345A (zh) | 一种与二甲双胍联合干预高血糖的含亚麻籽粉的功能性食品 | |
| KR20170064023A (ko) | 돼지감자 추출물을 함유하는 췌장베타세포 손상을 예방, 개선 또는 치료를 위한 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |